Actively Recruiting
Monitoring Immune Markers and Their Link to Ventilator-Associated Pneumonia Recurrence in ICU Patients
Led by Centre Hospitalier Intercommunal Aix-Pertuis · Updated on 2026-08-26
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients admitted to the Intensive Care Unit ICU who develop ventilator-associated pneumonia VAP. The study aims to explore how post-aggressive immunoparalysis, monitored by HLA-DR levels below recognized thresholds, relates to the recurrence of VAP. It also examines associations between immunoparalysis, death, severity of shock, viral reactivation, and infection persistence in a well-managed antibiotic setting. Participants will undergo blood collection for HLA-DR measurement at the time of enrollment and weekly thereafter. This observational study focuses on monitoring immunity markers rather than administering treatments. The study evaluates how immunoparalysis depth and duration correlate with VAP recurrence and other clinical outcomes during the hospital stay. Participants will have blood samples taken regularly to assess immune function, while researchers collect clinical data including infection recurrence, viral reactivation, and shock severity. The main outcome is the occurrence of VAP recurrence or relapse, assessed until hospital discharge or death. The study also monitors secondary outcomes over extended periods, with follow-up lasting until the end of hospitalization or death, up to 100 months.
CONDITIONS
Brief Title
Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia
Research Team
L
Laurent LEFEBVRE, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here